Drug Discovery
By
Will Merck’s CAPVAXIVE® 21-Valent Vaccine Set a New Benchmark in Pediatric Pneumococcal Protection After Phase 3 Success?
Key Highlights Promising Phase 3 Data from STRIDE-13 TrialMerck announced that CAPVAXIVE demonstrated robust immunogenicity and safety in…
Could Sanofi’s One-Time Gene Therapy SAR402663 Transform Treatment for Neovascular Age-Related Macular Degeneration?
Key Highlights A Major Step Forward in Retinal Disease InnovationThe FDA’s Fast Track designation underscores the urgent need…
Is Lilly’s “TuneLab” the Breakthrough AI Collaboration Model Biotech Startups Have Been Waiting For?
Key Highlights A bold move: Lilly democratizes AI for biotechEli Lilly has launched TuneLab, a novel AI platform…
Can Gilead’s Twice-Yearly Yeytuo® (Lenacapavir) Redefine HIV Prevention Across Europe With Zero Infections in Phase 3 Trials?
Key Insights: A Historic European Approval That Expands Prevention Choices The European Commission granted marketing authorization for Gilead’s…
Will Johnson & Johnson’s FDA Approval of INLEXZO™ Redefine Bladder Cancer Care After 40 Years of Limited Progress?
Key Highlights: A Breakthrough in Bladder Cancer TreatmentThe U.S. FDA has approved INLEXZO™ (gemcitabine intravesical system), marking the…
Could Johnson & Johnson’s MARIPOSA Trial with RYBREVANT® + LAZCLUZE® Transform First-Line EGFR-Mutated NSCLC Treatment?
Key Highlights: Clinical Breakthrough in EGFR-Mutated NSCLCJohnson & Johnson’s Innovative Medicine segment has announced positive results from the…
